A carregar...
Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib
PURPOSE: Acid-suppression therapy is known to decrease the systemic exposure of erlotinib. The erlotinib prescribing information also recommends staggering dosing with a histamine-2 receptor antagonist (H(2)RA) and avoiding concurrent use of a proton-pump inhibitor (PPI). This retrospective analysis...
Na minha lista:
| Publicado no: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4967016/ https://ncbi.nlm.nih.gov/pubmed/27372908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3087-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|